Improving lung cancer screening for smokers using DNA analysis
An Improved Epigenetic Algorithm for Guiding Low Dose CT Lung Cancer Screening
This study is looking at how to make lung cancer screening with low-dose CT scans better for smokers by using special DNA tests to find out who would benefit the most from the screening, helping to catch lung cancer earlier and improve treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bd Holding, INC. NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10890199 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of Low Dose Computerized Tomography (LDCT) for lung cancer screening in smokers by utilizing advanced epigenetic algorithms. The study aims to identify which smokers are most likely to benefit from LDCT screening based on their DNA methylation patterns. By analyzing specific genetic markers, the research seeks to develop a more precise method for determining eligibility for screening, potentially leading to earlier detection and better treatment outcomes for lung cancer. The approach combines cutting-edge technology with established biomarkers to refine screening recommendations.
Who could benefit from this research
Good fit: Ideal candidates for this research are current or recent smokers aged 50 to 80 who have a significant smoking history of 20 pack years or more.
Not a fit: Patients who have never smoked or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and effective lung cancer screening for smokers, improving early detection and treatment outcomes.
How similar studies have performed: Previous studies have shown promising results using similar epigenetic approaches to predict smoking status and screening benefits, indicating a strong potential for success in this research.
Where this research is happening
Iowa City, United States
- Bd Holding, INC. — Iowa City, United States (Active)
Researchers
- Principal investigator: Philibert, Robert a — Bd Holding, INC.
- Study coordinator: Philibert, Robert a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.